Boris V Janssen
Overview
Explore the profile of Boris V Janssen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
95
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bereska J, Zeeuw M, Wagenaar L, Jenssen H, Wesdorp N, van der Meulen D, et al.
Insights Imaging
. 2024 Nov;
15(1):279.
PMID: 39576456
Objectives: Total tumor volume (TTV) is associated with overall and recurrence-free survival in patients with colorectal cancer liver metastases (CRLM). However, the labor-intensive nature of such manual assessments has hampered...
2.
Janssen B, Oteman B, Ali M, Valkema P, Adsay V, Basturk O, et al.
Am J Surg Pathol
. 2024 Jul;
48(9):1108-1116.
PMID: 38985503
Neoadjuvant therapy (NAT) has become routine in patients with borderline resectable pancreatic cancer. Pathologists examine pancreatic cancer resection specimens to evaluate the effect of NAT. However, an automated scoring system...
3.
Stoop T, Oba A, Wu Y, Beaty L, Colborn K, Janssen B, et al.
JAMA Netw Open
. 2024 Jun;
7(6):e2417625.
PMID: 38888920
Importance: Preoperative chemo(radio)therapy is increasingly used in patients with localized pancreatic adenocarcinoma, leading to pathological complete response (pCR) in a small subset of patients. However, multicenter studies with in-depth data...
4.
Bereska J, Janssen B, Nio C, Kop M, Kazemier G, Busch O, et al.
Eur Radiol Exp
. 2024 Feb;
8(1):18.
PMID: 38342782
Objective: This study aimed to develop and evaluate an automatic model using artificial intelligence (AI) for quantifying vascular involvement and classifying tumor resectability stage in patients with pancreatic ductal adenocarcinoma...
5.
Ingwersen E, Bereska J, Balduzzi A, Janssen B, Besselink M, Kazemier G, et al.
BJS Open
. 2023 Oct;
7(5).
PMID: 37811791
Background: Accurately predicting the risk of clinically relevant postoperative pancreatic fistula after pancreatoduodenectomy before surgery may assist surgeons in making more informed treatment decisions and improved patient counselling. The aim...
6.
Ramaekers M, Viviers C, Janssen B, Hellstrom T, Ewals L, van der Wulp K, et al.
J Clin Med
. 2023 Jul;
12(13).
PMID: 37445243
Radiological imaging plays a crucial role in the detection and treatment of pancreatic ductal adenocarcinoma (PDAC). However, there are several challenges associated with the use of these techniques in daily...
7.
Balduzzi A, Janssen B, De Pastena M, Pollini T, Marchegiani G, Marquering H, et al.
Br J Surg
. 2023 Jul;
110(12):1623-1627.
PMID: 37402951
No abstract available.
8.
Augustinus S, Schafrat P, Janssen B, Bonsing B, Brosens L, Busch O, et al.
Ann Surg Oncol
. 2023 May;
30(8):5051-5060.
PMID: 37210448
Background: Surgeons aim for R0 resection in patients with pancreatic cancer to improve overall survival. However, it is unclear whether recent changes in pancreatic cancer care such as centralization, increased...
9.
10.
Janssen B, van Roessel S, van Dieren S, de Boer O, Adsay V, Basturk O, et al.
Br J Surg
. 2022 Nov;
110(1):67-75.
PMID: 36331867
Background: Most tumour response scoring systems for resected pancreatic cancer after neoadjuvant therapy score tumour regression. However, whether treatment-induced changes, including tumour regression, can be identified reliably on haematoxylin and...